Astrazeneca Pharma India Q1 Profit Falls 32% to ₹37.93 Crore on Higher Expenses

The company had posted a profit after tax of ₹55.83 crore in the corresponding quarter last fiscal year, AstraZeneca Pharma India Ltd (AZPIL) said in a regulatory filing. Revenue from operations in the first quarter stood at ₹682.79 crore as against ₹526.31 crore in the corresponding period a year ago, it added. Total expenses during the quarter were higher at ₹641.03 crore, as compared to ₹462.49 crore in the year-ago period, the company said. During the quarter, the company said it strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives and advanced strategic partnerships that support earlier diagnosis and broader access.